Because of its potent reduction of tumor burden, Omomyc stands as the first direct MYC inhibitor to ascend in dose-escalated phase 1 and phase 2 clinical trials of patients with non-small cell lung, colorectal, and breast cancer (NCT04808362). The gene discussed is MYC; the disease is neoplasm.